Mechanisms of Immunosurveillance for Lung Cancer

Study summary

The purpose of this research study is to investigate the differences in "natural killer (NK) blood cells, a type of white blood cell that fights infection in the body, among different types of patients that have lung surgery. The four different groups of patients are: * smokers with lung cancer * smokers without lung cancer * non-smokers with lung cancer * non-smokers without lung cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedblood draw

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 7, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Washington University School of Medicine

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Washington University School of Medicine
Interventions being studied: Other: blood draw

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Surgery→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Age equal or greater to 18 years
Ability to read and write in English
Able to participate in the informed consent process

Reasons someone may not be able to joinExclusion criteria

Known active hepatitis B, hepatitis C, or HIV/AIDs (found in medical record)
Chemotherapy or radiation therapy within 3 months of enrollment
Type 1 Diabetes Mellitus
Rheumatoid arthritis, Lupus, Multiple Sclerosis, or any other autoimmune disease as deemed necessary for exclusion by the Principal Investigator
Previous organ transplant
Blood transfusion within 3 months prior to enrollment
Any previous cancer, excluding a previous lung cancer
Steroid use within 4 weeks of enrollment

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Washington University School of MedicineSt Louis, Missouri

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 7, 2018. Always confirm current availability with the study team.

View original record ↗